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Objective: We compared conventional treatment with pumpless extracorporeal lung
membrane (Interventional Lung Assist [iLA] Novalung; Novalung GmbH, Hechin-
gen, Germany) support in a pig model of postpneumonectomy severe acute respira-
tory distress syndrome.
Methods: Adult pigs underwent a left thoracotomy without (group I) or with a left ex-
trapericardial pneumonectomy and radical lymphadenectomy (groups II to V). After
stabilization, pigs belonging to group II were observed only, whereas in those belong-
ing to groups III to V, a surfactant-depletion severe (PaO2/FIO2 , 100) postpneumo-
nectomy acute respiratory distress syndrome was induced. This was followed by
observation (group III); treatment with conventional therapy including protective ven-
tilation, steroids, and nitric oxide (group IV); or femoral arteriovenous iLA Novalung
placement, near-static ventilation, steroids, and nitric oxide (group V). Each group
included 5 animals. Primary outcome was extubation 12 hours postoperatively or
postpneumonectomy acute respiratory distress syndrome.
Results: A severe postpneumonectomy acute respiratory distress syndrome was ob-
tained after 96 2 alveolar lavages over 906 20minutes. In group V pigs, the iLANo-
valung device diverted 17%6 4% of the cardiac output, permitted an oxygen transfer
and carbon dioxide removal of 298.46 173.7 mL/min and 287.76 87.3 mL/min, re-
spectively, and static ventilation (tidal volume, 2.26 1mL/kg; respiratory rate, 66 2.9
breaths/min). All but 1 pig belonging to group V could be extubated compared with
none in groups III and IV (P, .01), and only their lungs normalized cytokine release
(P, .001) and surfactant (P, .03) anddisplayed fewer parenchymal lesions (P, .05).
Conclusions: The pumpless extracorporeal lung membrane and near-static ventilation
achieved a significantly better outcome than conventional treatment in this pig model
of severe postpneumonectomy acute respiratory distress syndrome, probably because
the injured lungs were not forced to work and this ‘‘rest’’ gave themmore time to heal.
P
ostpneumonectomy acute respiratory distress syndrome (ppARDS) is a rare1
but lethal complication. Its conventional treatment includes early intubation
and mechanical ventilation (MV), diuresis to improve fluid balance, broad-
spectrum antibiotic coverage, aggressive pulmonary toilet including aspiration bron-
choscopy and frequent position changes, as well as intravenous steroid therapy.2
Unfortunately, current mortality rates still range from 30% to 100%, and most deaths
are related either to the potential comorbidity or, more likely, to the further ventila-
tory-induced lung injury of the residual aerated and potentially recruitable lung re-
gions. There is, therefore, a clear need for therapeutic innovations in these patients.
In a recent clinical investigation, we3 observed that the combination of a pumpless
extracorporeal lung membrane (interventional lung assist [iLA] device, Novalung;
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PAbbreviations and Acronyms
ARDS 5 acute respiratory distress syndrome
AVCO2R 5 extracorporeal carbon dioxide removal
BAL 5 bronchoalveolar lavage
CO 5 cardiac output
FIO2 5 inspired oxygen fraction
IL 5 interleukin
iLA 5 interventional lung assist
MV 5 mechanical ventilation
OR 5 odds ratio
PEEP 5 positive end-expiratory pressure
ppARDS 5 postpneumonectomy acute respiratory
distress syndrome
TNF-a 5 tumor necrosis factor a
Novalung GmbH, Hechingen, Germany) to near-static venti-
lation was able to significantly reduce the mortality rate of
patients with severe ppARDS unresponsive to conventional
treatment. In parallel with this, we conducted an experimental
study aiming to develop a pig model of severe ppARDS and
compare conventional treatment to the iLA support and static
ventilation, and the results are presented here.
Material and Methods
Yorkshire Duroc pigs (Isoquimen S/L, 08080 Barcelona, Spain)
weighing between 50 and 60 kg were used. All animals received
care in compliance with the ‘‘Principles of Laboratory Animal
Care’’ formulated by the National Society for Medical Research
and the ‘‘Guide for the Care and Use of Laboratory Animals’’ pre-
pared by the Institute of Laboratory Animal Resources, National
Research Council, and published by the National Academy Press,
revised 1996. The study was approved by the Animal Care and
Use Committee of the University of Barcelona (Project N-0001-
61399030-F).
Study Design
The experimental design is outlined in Figure 1. After instrumenta-
tion, pigs were placed in the right lateral decubitus position and ran-
domly underwent a left thoracotomy without (group I) or with a left
extrapericardial pneumonectomy and radical lymphadenectomy
(groups II to V). After stabilization in the decubitus dorsalis posi-
tion, pigs belonging to groups I and II were observed whereas in
those belonging to groups III to V, a surfactant-depletion ppARDS
was induced followed by observation (group III), treatment with
conventional therapy including protective ventilation, steroids,
and nitric oxide (group IV), or femoral arteriovenous iLA placement
and near-static ventilation (group V). Each group included 5 ani-
mals. Primary outcome was extubation 12 hours postoperatively
or ppARDS. The observation and treatment times were 12 hours
in each group, after which the animals were weaned if the following
criteria were met: awakens, respiratory rate less than 30 breaths/min,
PaO2 greater than 60 mm Hg, and PaCO2 less than 55 to 60 mm Hg
under pressure support ventilation with a positive end-expiratory
pressure (PEEP) of 5 cm H2O and a fraction of inspired oxygenThe Journal of Thor(FIO2) of 0.4. Otherwise, or at the first evidence of vital stress,
animals were humanely killed.
Anesthesia and Monitoring
Animals were premedicated with intramuscular azaperone (4 mg/
kg) and intravenous thiopental (10 mg/kg), and relaxation was in-
duced with intravenous rocuronium (6 mg $ kg21 $ h21). Orotra-
cheal intubation was done via a 7.5F endotracheal tube under
bronchoscopic guidance. Animals were ventilated with volume
control (Servo 900D; Siemens-Elema, Stockholm, Sweden) with
the following respiratory settings: respiratory rate, 20 to 25
breaths/min; tidal volume, 10 to 12 mL/kg; FIO2, 1.0, and PEEP, 5
cm H2O. Anesthesia was maintained via continuous infusion of fen-
tanyl (1 mg $ kg21 $ h21) and propofol (3–5 mg $ kg21 $ h21) until
the end of the study. At induction of anesthesia, intravenous cefazo-
lin (2 g) was administered and every 6 hours thereafter until the end
of the study. Animals were instrumented with an arterial pressure
line (5F) placed transcutaneously in the right femoral artery (PiCCO
plus; Pulsion Medical Systems, Munich, Germany), several periph-
eral venous catheters, and a thermodilution catheter (Swan-Ganz
catheter; Edwards LifeSciences, Munich, Germany) placed transcu-
taneously through the left internal jugular vein to the right retrocaval
pulmonary artery under fluoroscopic guidance.
Peripheral oxygen arterial saturation and urine output were con-
tinuously monitored with a pulse oximeter (BCI Inc, Waukesha,
Wis) placed at the pig’s tail and a percutaneous bladder catheter, re-
spectively. Body temperature was maintained at 37C with heaters
and blankets. Fluid management included continuous infusion of
0.9% NaCl at a rate of 100 mL/h with the following exceptions:
(1) if mean arterial pressure was less than 60 mm Hg or central ve-
nous pressure was less than 4 mmHg, an additional 100 mL of 0.9%
NaCl was infused over 6 minutes; and (2) if central venous pressure
was greater than 8 mm Hg, the continuous infusion was stopped
until it returned to within the goal range of 4 to 8 mm Hg. Postop-
eratively, the target overall fluid load was kept 60 mL. Inotropic
and intravenous norepinephrine 5 mL/h was given if systemic sys-
tolic arterial pressure dropped to less than 100 mm Hg, and intrave-
nous atropine (0.5–1 mg) was given if heart rate was less than 50
beats/min.
Surgery
Surgical procedures were performed under sterile conditions and on
the right lateral decubitus position. All animals underwent a left pos-
terolateral muscle-sparing thoracotomy in the fourth intercostal
space with or without an extrapericardial pneumonectomy and rad-
ical mediastinal lymphadenectomy. In pigs undergoing resection,
the hemiazygos vein was divided and ligated to enhance exposure
of the left hilum followed by division of the inferior pulmonary lig-
ament up to the level of the inferior pulmonary vein. After intrave-
nous administration of heparin sodium (200 IU/kg), the inferior and
superior pulmonary veins were individually clamped, divided, and
sutured with a running 5–0 polypropylene suture (Prolene; Ethicon,
Inc, Somerville, NJ), as was the left pulmonary artery. The left main
bronchus was then dissected, sectioned, and sutured with interrupted
polyglactin sutures (Vicryl; Ethicon) according to the Overholt tech-
nique, and its closure was checked under a pressure of 40 mm Hg
saline. Finally, all ipsilateral lymph nodes of the upper and lower
mediastinum were resected.acic and Cardiovascular Surgery c Volume 135, Number 6 1363
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Figure 1. Study design. VT, Tidal volume;
VM, minute volume; RR, respiratory rate;
PEEP, positive-end expiratory pressure;
NO, nitric oxide; iLA, interventional lung
assist device.After detailed hemostasis, a 36F chest tube was placed through in
the second intercostal space and the chest closed in layers. At the
completion of the procedure, 2mL of 0.25% bupivacaine hydrochlo-
ride (Bupivacaine Braun; B. BraunMedical Inc, Bethlehem, Pa) was
given for a fourth intercostal nerve block.At the end of the procedure,
pigs were placed in the supine position and stabilized for 1 hour.
Induction of ARDS
The commonly used surfactant-depletion model of Lachmann, Rob-
ertson, and Vogel4 was adapted to develop a ppARDS. This model
reproduces arterial blood gases and radiographic and histologic
changes of the lung similar to those seen in patients with ARDS. Af-
ter the left pneumonectomy and lymphadenectomy, pigs were stabi-
lized in the supine position for 1 hour. Thereafter, the endotracheal
tube was disconnected from the ventilator, and prewarmed (37C)
sterile saline (12–15 mL/kg per lavage) was instilled, using gravity,
via the endotracheal tube into the right lung until a fluid meniscus
level was seen in the endotracheal tube. After 1 minute of apnea,
the fluid was gravity-drained and the recovered volume was mea-
sured. During the lavage (duration approximately 45–60 seconds),
airway pressure was measured and not allowed to rise above 40
cm H2O. Ventilation (tidal volume 20 mL/kg, PEEP 3 cm H2O, re-
spiratory rate 15–20 breaths/min, FIO2 1.0.) was resumed for 10 min-
utes after each lavage while PaO2 was continuously measured to
assess lung injury. This procedure was repeated until a severe
ARDS was evident (defined as a PaO2/FIO2 ratio of less than 100
after 10 minutes of ventilation after lavage), and this time point
was set as the occurrence of the severe ppARDS. Subsequently,
animals were randomly assigned to observation, treatment with pro-
tective ventilation or iLA, and near-static ventilation.
During the procedure, peripheral oxygen saturation was docu-
mented continuously and blood samples were continuously taken1364 The Journal of Thoracic and Cardiovascular Surgery c Jfor determination of PaO2, PaCO2, and pH via conventional tech-
niques. The criteria followed for defining an ARDS were those pro-
posed by the American–European Consensus Conference5 in 1994
that evaluates time to appearance, oxygenation (PaO2/FIO2 ratio), ra-
diographic infiltrates, and pulmonary capillary wedge pressure. The
clinical severity of the ARDS was calculated according to the defi-
nition of Murray and associates,6 which evaluates radiographic con-
solidation, hypoxemia, level of PEEP, and static lung compliance,
whereby ARDS may be mild (1–2.5) or severe (.2.5).
iLA Implantation Technique
The iLA device was placed via transcutaneous Seldinger tech-
nique, cannulating first the femoral artery and then the ipsilateral
vein with Novalung arterial (15F) and venous (17F) cannulas,
respectively. Cannulas were advanced maximally, flushed with a bo-
lus of about 50 mL of heparinized saline (heparin doses 10–20 IU/kg
body weight), and clamped proximally. The deaired and filled
(240 mL of saline) iLA device was then connected to both previ-
ously placed cannulas after complete deairing of the connecting
lines. Before declamping, all connections were secured. The iLA
was declamped gently and progressively over 1 to 2 minutes to min-
imize the hemodynamic effects of the induced femorofemoral arte-
riovenous shunt.
An oxygen supply line was connected to the inflow site of the
membrane oxygenator with oxygen flow of 6 to 12 L/min. A bidirec-
tional ultrasonic flow probe sensor (Novalung Emtec) placed at the
outflow venous line monitored device flow. Device functional con-
trol was achieved through a monitor (Blood Flow Monitor; Nova-
lung) that calculates blood flow through the system using the
ultrasonic flow probe. Malfunction of the iLA was defined as a driv-
ing blood flow of less than 0.5 L/min. The systemic arterial organ
perfusion had to maintain 100 mm Hg pressure, eventually withune 2008
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Pthe aid of vasoactive drugs, as well as an activated clotting time of
approximately 180 to 200 seconds with heparin if necessary.
The capability of the iLA to provide additional oxygen was mea-
sured by calculating the oxygen content of blood entering and exit-
ing the device and multiplying the difference by the flow rate
through the device, according to the following formula: Oxygen
transfer (mL/min) 5 ([Oxygen content as volume percent] 3 10
dL/L) 3 iLA flow rate (L/min).
Arteriovenous extracorporeal carbon dioxide removal (AV-
CO2R) provided by the iLA was calculated as follows: AVCO2R
(mL/min)5Carbon dioxide content in the inflow arterial cannula2
Carbon dioxide content in the venous outflow cannula (mL carbon
dioxide/100 mL blood) 3 Blood flow iLA (L/min) 3 10.
E-Hemodynamic and Lung Function
The following hemodynamic variables were measured at baseline,
during left pneumonectomy, at induction of the ppARDS, and hourly
until the end of study (Monitor Hewlett-Packard model 685; Hew-
lett-Packard Company, Palo Alto, Calif): heart rate, cardiac output
(CO), cardiac index, mean arterial pressure, mean pulmonary arterial
pressure, pulmonary capillary wedge pressure, central venous pres-
sure, systolic index, systolic volume, systemic vascular resistance,
pulmonary vascular resistance, left ventricular systolic work, right
ventricular systolic work, mixed venous oxygen saturation, and
body temperature through the Swan-Ganz cathether.
PiCCO measured extravascular lung water volume, ventricular
contractibility, and permeability vascular pulmonary index. Ventila-
tor parameters, including minute volume, tidal volume, lung compli-
ance, and peak airway inspiratory pressure, as well as arterial blood
gases, were evaluated hourly.
E-Lung Cytokine Assays and Surfactant evaluation
The right lung was washed with 40-mL aliquots of sterile saline so-
lution (0.9% NaCl) instilled through the bronchoscope’s channel
and subsequently aspirated manually before intubation and every
hour thereafter. Tumor necrosis factor a (TNF-a) and interleukin
(IL) 6 and 8 levels were measured in bronchoalveolar lavage
(BAL) supernatants by using an enzyme-amplified sensitivity
immunoassay based on the quantitative immunometric sandwich
enzyme immunoassay technique (Medgenix Diagnostics, Fleurus,
Belgium, and PerSeptive Biosystems, Inc, Framingham, Mass). At
the same time, we assessed surfactant measurements in BAL by
fluorescence polarization based on the quantitative lecithin/albumin
ratio (TDx/TDxFLx Fetal Lung Madurity II; Abbott Laboratories,
Chicago, Ill). Normal concentration ranges in our laboratory are
as follows: TNF-a (25–120 mg/mL), IL-6 (,39 mg/mL), IL-8
(,62 mg/mL), and mature surfactant (.40 mg/g).
E-Histopathologic Features
Animals were humanely killed 12 hours postoperatively or after
ppARDS or if the animal’s condition was deteriorating. Death was
induced by an intravenous bolus of fentanyl, propofol, and potas-
sium chloride (40 mEq). Systemic heparin (100 IU/kg) was also
given to avoid postmortem thrombus formation. The lung tissue
samples of each lobe were dissected, placed in formalin for 24 hours,
and embedded in paraffin overnight. The paraffin blocks were cut in
sections measuring 5 mm, mounted on glass slides, and stained with
hematoxylin and eosin. Each section was evaluated to search for des-The Journal of Thoraquamation of bronchial and bronchiolar epithelium. We also sought
the presence of hyaline membranes and accumulations of pyknotic
cells in preterminal air spaces or recent peribronchial inflammatory
changes, characterized by edema and infiltration of polymorphonu-
clear leukocytes and eosinophils. Accordingly, a histologic classifi-
cation of the ppARDS was developed that takes into account the
severity and extent of the encountered lesions (Table E1).
Statistical Analysis
Continuous variables were compared by independent-samples t test.
To perform between-groups comparisons of categorical variables,
we calculated the odds ratio. Results are presented as mean 6 stan-
dard error of mean. Analyses were made with the SPSS package
(version 7.0; SPSS, Inc, Chicago, Ill).
Results
Thirty-one animals were necessary to complete the 25-animal
study; 6 either died during surgery (n 5 1) or did not hemo-
dynamically tolerate the lavages (n 5 5). Pneumonectomy-
only pigs had a significantly (P , .05) lower CO and higher
systemic and pulmonary vascular resistances than did the
thoracotomy-alone pigs. The volume of saline instilled and
necessary to obtain a severe ppARDS in pigs belonging to
groups III to V was 9.25 6 1.73 L given via 9 6 2 lavages
and over 90 6 20 minutes and was associated with a signifi-
cant respiratory and hemodynamic deterioration compared
with pigs belonging to groups I and II; there were, however,
no severity differences in the ppARDS pigs (Table 1). The
volume of saline returned was 9.15 6 1.5 L, with a positive
balance of 100 6 35 mL.
The iLA diverted 1.36 0.2 L/min or 16.8%6 4.5% of the
CO, but the resulting arteriovenous shunt effect was well tol-
erated clinically in pneumonectomized pigs (Table E2). The
iLA device allowed an oxygen transfer and carbon dioxide
removal (AVCO2R) of 298.4 6 173.7 mL/min and 287.7 6
87.3 mL/min (Figure E1), respectively; consequently, the
respiratory settings of MV in iLA-supported pigs could be
significantly lowered to reach near static ventilation (tidal
volume, 2.2 6 1 mL/kg; respiratory rate, 6 6 3 beats/min).
The combination of iLA and near-static ventilation resulted
in a significantly better and early recovery of the respiratory
and mechanical functions of the injured lung, tissue perfu-
sion, and oxygenation compared with group III and IV pigs
(Table 2).
As expected, pigs belonging to groups I and II could be
extubated. None of the animals belonging to groups III and
IV could be weaned; they died within 3 6 1 and 10 6 2
hours, respectively, of progressive respiratory failure (P ,
.01). Four (80%) of the 5 pigs treated with iLA and near-static
ventilation fulfilled the extubation criteria (P , .01) and
could be weaned; none of the pigs belonging to group III
or IV survived. At planned death or extubation, pigs belong-
ing to group V had a significantly less severe Murray score
than pigs belonging to groups IV and III (P , .05)
(Figure 2) The postmortem specimen, group V treated lungscic and Cardiovascular Surgery c Volume 135, Number 6 1365
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Variables Group I Group II Group III Group IV Group V P value
Lavages (No.) — — 9 6 2 8 6 1 9 6 2 NS
Onset ppARDS (min) — — 90 6 10 90 6 15 90 6 20 NS
PaO2/FIO2 ratio 411 6 90 341 6 94* 81.3 6 8.7 86.6 6 19.6 86.4 6 4.2 .001
PaCO2 (mm Hg) 36 6 5 38 6 7* 63.9 6 7.5 57.1 6 9.26 63.6 6 13.9 .02
sLC (mL/cm H2O) 60 6 2.5 57 6 4* 19.7 6 5.5 20 6 3.2 216 2.1 .05
CO (L/min) 5.6 6 1.5 4 6 1.2 5.7 6 2 6.4 6 1 6.4 6 2 .05
MAP (mm Hg) 79 6 16 81 6 6 86 6 2 71 6 7 70 6 2 NS
MPAP (mm Hg) 26 6 3.6 30.4 6 4.7 40.5 6 6 39 6 7 37.5 6 8.3 NS
SVR (dynes/cm5) 1031 6 422 1405 6 456* 772 6 522 748 6 94 662 6 236 .05
PVR (dynes/cm5) 157.7 6 38 354.5 6 126 478 6 147 304 6 45.4 270 6 72.8 NS
PCWP (mm Hg) 15 6 2 13.5 6 1.6 12.5 6 2.5 13.2 6 3.5 13.2 6 3.1 NS
Dpmax (mm Hg) 531 6 161 461 6 207 510 6 256 986 6 310 1093 6 383 NS
PVPI 2.5 6 0.8 1.9 6 0.4 5.9 6 3.1 4.6 6 2.4 4 6 0.5 .01
SvO2 (%) 75 6 4.3 80 6 8* 63 6 1 61 6 4 65.5 6 2 .05
Murray score 0 0 3.6 6 0.5 3.6 6 0.5 3.6 6 0.5 ,.05
Respiratory and hemodynamic differences between various groups of pigs: Group I, Pigs treated with left thoracotomy alone without left pneumonectomy and
radical lymphadenectomy; group II, pigs treated with left thoracotomy with left pneumonectomy and radical lymphadenectomy; group III, pigs treated like
group II plus a surfactant depletion of the residual right lung without any further treatment; group IV, treatment with protective ventilation; group V, treatment
with extracorporeal lung membrane and near-static ventilation. NS, Not significant; PaO2/FIO2, arterial oxygen tension/fraction of inspired oxygen; PaCO2,
arterial carbon dioxide tension; sLC, static lung compliance ([Tidal volume/End-expiratory plateau pressure]2 PEEP); CO, cardiac output;MAP, mean arterial
pressure; MPAP, mean pulmonary arterial pressure; SVR, systemic vascular resistance; PVR, pulmonary vascular resistance; PCWP, pulmonary capillary
wedge pressure; Dpmax, ventricular contractibility; PVPI, permeability vascular pulmonary index; SvO2, mixed venous oxygen saturation; Murray score, se-
verity of ARDS (05 no distress; 0.1–2.55 mild;.2.5 5 severe). Data were collected and compared at induction of ARDS. *Indicates significance between
groups III/IV and V.had a lower dry/net weight ratio (222 vs 320 vs 343 g) and
significantly (P , .05) less severity and extent of ARDS
lesions than pigs treated conventionally (Table 3).
The injured lungs released significantly (P , .001) more
cytokines during induction of the ppARDS (Figure 3).
Lung cytokines normalized during the treatment period
only in iLA-treated pigs but not in those managed with obser-
vation and protective ventilation or conventional treatment
(P , .05) (Figure 4). Table E3 outlines the evolution of the
different lung cytokines TNF-a, IL-6, and IL-8 over time.
The quantification of the depletion of the surfactant, as1366 The Journal of Thoracic and Cardiovascular Surgery c Jpointed out in Figure 5, clearly shows that near-static venti-
lation allowed a significantly better recovery of the surfactant
than protective ventilation.
Discussion
The surfactant depletion model of Lachmann, Robertson, and
Vogel4 used in this study to obtain a severe ppARDS was
chosen for two reasons: (1) it induces lung failure before
the development of parenchymal remodeling and/or fibrosis
takes place, similarly to what is observable in neonatal respi-
ratory distress syndrome and in early acute lung injury inTABLE 2. Respiratory, gas exchange, and lung compliance variables in ppARDS pigs treated with observation only (group
III), protective ventilation (group IV), or extracorporeal lung membrane (iLA) support (group V)
Variables Group III Group IV Group V P value
Tidal volume (mL) 590 6 57.4 373 6 46.4 131 6 40* ,.001
Respiratory rate (bpm) 17 6 2 19.5 6 0.8 6 6 3* ,.001
Minute volume (L/min) 10.4 6 0.5 7.7 6 1.1 1.1 6 0.7* ,.001
End-inspiratory plateau pressure (cm H2O) 37 6 5.8 32 6 6.7 23.7 6 2.1* ,.001
PEEP (cm H2O) 5 11.6 6 2.1 19.5 6 1.8* ,.001
PaO2/FIO2 ratio 63 6 16 180 6 87 235 6 78* ,.001
PaCO2 (mm Hg) 75 6 4 93.3 6 28 61 6 14* ,.001
Mixed venous oxygen saturation (%) 53.3 6 14 74.2 6 9 83 6 5.5* ,.001
Static lung compliance (mL/cm H2O) 19 6 4 20 6 7 46 6 28* ,.001
ppARDS, Postpneumonectomy acute respiratory distress syndrome; PaO2/FIO2, arterial oxygen tension/fraction inspired oxygen; PaCO2, arterial carbon dioxide
tension; lung compliance was calculated as ([Tidal volume/End-inspiratory plateau pressure] 2 Positive end-expiratory pressure). *Statistically significant
difference. Comparison was made between groups V and III/IV.une 2008
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PFigure 2. Selective chest x-ray of the right lung taken in pigs instrumented with left pneumonectomy and radical
lymphadenectomy without (A, 12 hours postoperatively; Murray score: 0) or with surfactant depletion of the right
lung (B, at the onset of a severe postpneumonectomy acute respiratory distress syndrome (ppARDS); Murray score:
3.6 6 0.5) observed only (C, 3 hours postoperatively), treated with conventional treatment (D, 6 hours ppARDS;
Murray score: 2.26 0.5) or extracorporeal lung membrane (E, 12 hours ppARDS; Murray score: 16 0.5). The severity
of the ARDS was calculated according to Murray and associates6 and evaluates radiographic consolidation, hyp-
oxemia, level of PEEP, and static lung compliance, whereby ARDS may be absent (0) mild (1–2.5), or severe (>2.5).adults; (2) it represents a suitable platform for ventilating in-
jured lungs with high PEEP and low tidal volume.7 This
ppARDS investigation was made in adult pigs and thus can-
not be directly extrapolated to the clinical setting. With that
stated, however, this model does mimic most of the condi-
tions encountered in patients with severe ppARDS,3 and it
provides evidence that a therapeutic strategy prioritizing
a maximal reduction (tidal volume 1–2 mL/kg; respiratory
rate 5–8 beats/min) of the alveolar ventilation is associatedThe Journal of Thorawith a significantly better prognosis than established protec-
tive ventilation settings (tidal volume 6 mL/kg; respiratory
rate 15–20 beats/min).
A severe ppARDS was observed within 2 hours of de-
pleting the surfactant of the residual right lung, and the pre-
sented data showed that it manifested itself constantly with
a profound hypoxia of noncardiac origin, acute and persis-
tent pulmonary inflammation with increased vascular per-
meability, and diffuse infiltrates demonstrable on chestcic and Cardiovascular Surgery c Volume 135, Number 6 1367
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CSPTABLE 3. Severity and extend of ARDS lesions between pigs treated with left thoracotomy (group I) or pneumonectomy
alone (group II), depletion of surfactant followed any further treatment (group III), conventional treatment (IV) or
extracorporeal lung membrane and near-static ventilation (group V)
Group I Group II Group III Group IV Group V P value
No. of survivors (%) 5/5 (100%) 5/5 (100%) 0/5 (0%) 0/5 (0%) 4/5 (80%)* ,.001
Survival (h) 12 12 3 6 1 10 6 2 12* ,.05
Extubation (%) 100% 100% 0% 0% 80% ,.001
Lung histology (grading, 0–3):
Atelectasis 0.2 6 0.1 0.2 6 0.4 1.2 6 0.4 1.4 6 0.5 0.4 6 0.3 NS
Bronchial epithelium desquamation 0.2 6 0.1 0.2 6 0.1 1.4 6 0.5 1.2 6 0.4 1 6 0.7 NS
Hyaline membranes 0 0 1.4 6 0.5 2.2 6 0.8 0.4 6 0.2* ,.01
Exudative interstitial lesions 0.2 6 0.1 0.2 6 0.1 2 6 0.7 2 6 1 1 6 0.7* .03
Exudative alveolar lesions 0.2 6 0.1 0.2 6 0.1 2.2 6 0.8 1 6 0.7 0.8 6 0.5* ,.03
Total severity grading 0.16 6 0.1 0.16 6 0.1 1.6 6 0.6 1.6 6 0.6 0.7 6 0.4* ,.05
Severity of extension lesions (grading, 0–3) 0.4 6 0.1 0.2 6 0.1 2.4 6 0.8 2.2 6 0.4 1.4 6 0.8 NS
ARDS, Adult respiratory distress syndrome; NS, not significant. *Indicates significance (P , .05) between group IV and V.radiographs in all animals. The learning curve of the model
was very important and mostly related to the hemodynamic
instability observed during the depletion of the surfactant.
We found that the instillation of the prewarmed saline via
the endotracheal tube was better tolerated hemodynamically
if adapted to the degree of peripheral arterial saturation
recovery, level of percutaneous carbon dioxide, and rise of
mean pulmonary artery pressure reached after each lavages
rather than the given amount of saline. Practically, it would
be better to deliver one or two lavages more rather than take1368 The Journal of Thoracic and Cardiovascular Surgery c Juthe risks to have a hemodynamic (and respiratory) unre-
sponsive failure.
The pathophysiologicmechanisms bywhich surfactant de-
pletion, documented by the dramatic fall of surfactant in the
BALs, resulted in a severe ARDS of the residual lung may
have occurred because surfactant depletion increased alveolar
surface tension, decreased negative pressure surrounding the
alveolar vessels, and this in turn increased transmural pres-
sure, fluid filtration, and endothelial and alveolar epithelial
permeability.8 These working hypotheses are indirectlyFigure 3. Dynamic of the cytokines (IL-6, IL-8, and TNF-a) release
of the right lung in pigs treated with left thoracotomy alone (group
I), pneumonectomy with radical lymphadenectomy alone (group
II), or depletion of surfactant of the right lung followed any further
treatment (group III), conventional treatment (IV), or extracorpo-
real lung membrane and near-static ventilation (group V). The sig-
nificant (P < .001) increase observed in group III was observed
especially during the first hour. Normal concentration ranges in
our laboratory are as follows: TNF-a (25–120 mg/mL), IL-6 (<39
mg/mL), and IL-8 (<62 mg/mL).nFigure 4. Dynamic of lung cytokines during the treatment periods
in pigs with a post-pneumonectomy acute respiratory distress
syndrome (ppARDS) observed only (group III), treated with con-
ventional therapy (group IV), or extracorporeal lung membrane
(iLA) and near-static ventilation (group V). Lung cytokines dropped
during treatment and not during observation (pig survival, 3 6 1
hours); however, only in iLA-treated pigs the cytokines returned
within normal range (P < .05) and not in pigs belonging to group
IV (10 6 2 hours). The survival of pigs treated with iLA support
in combination with near-static ventilation was 80% and fulfilled
the extubation criteria (P< .01). Normal concentrations ranges in
our laboratory are as follows: TNF-a (25–120 mg/mL), IL-6 (<39 mg/
mL), and IL-8 (<62 mg/mL).e 2008
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Pconfirmed by the analysis of the postmortem specimen of the
right lungs of pigs receiving a surfactant-depletion ppARDS
left untreated, where extensive exudative interstitial and alve-
olar lesions were noticed and responsible for the lung inflam-
mation reactions. The possibility that standard MV (tidal
volume 10–12 mL/kg; minute volume 10 L/min) could have
amplified the induced ppARDS may be extrapolated from
the unchanging expression of inflammatory mediators in the
BAL fluid of ppARDS lungs treated with standard MV set-
tings alone. All this evidence reinforces previous experimen-
tal and clinical observations that (1) the genesis of lung injury
in acute lung injury/ARDS is multifactorial but once estab-
lished involves the complex interplay of proinflammatory
and antiinflammatory mediators9,10 and (2) MV can both in-
duce and/or amplify lung injury because of the myriad of in-
teractions between the mechanical ventilator, inspired
oxidizing gazes, inflammatory mediators, and the lung.11–13
During primary acute lung injury/ARDS, the oxygenation
failure is almost completely the result of the loss of aerated
lung volume owing to atelectasis formation, mainly in the de-
pendent lung areas, and therefore the formation of an intrapul-
monary shunt. Consistently, the reopening of those atelectasis
areas results in an improved gas exchange. Therefore, it has
been the aim of numerous therapeutic strategies to recruit
these otherwise nonventilated lung zones. Although MV
with PEEP is lifesaving and without alternative in many of
these patients, it has become more and more obvious during
recent years that MV as such can contribute to or even pro-
mote lung damage, especially when high pressures and vol-
umes are used, which often seems necessary to restore
oxygenation. Accordingly, lung protective ventilation strate-
gies have been developed that in general should avoid further
lung damage by reducing tidal volume and distending airway
pressure during MV. These strategies obviously might not
Figure 5. Dynamic of the surfactant level in the right lung man-
aged with a postpneumonectomy acute respiratory distress syn-
drome. There was a significant (P < .05) recovery of surfactant
alveolar levels at 12 hours in iLA- treated pigs (group V) compared
with the conventional treatment (group III).The Journal of Thornecessarily be used to restore gas exchange to normal values.
However, outcome studies have clearly shown that it is more
essential to protect the lung from further damage than to nor-
malize blood gas values.14
Lung protective ventilation strategies all substantially
reduce alveolar ventilation by decreasing tidal volume and
plateau pressure, and some of them also reduce respiratory
frequency. There is currently a large body of evidence that re-
duction of tidal volume and distending pressures significantly
improves clinical outcome in acute lung injury/ARDS.14 The
resulting carbon dioxide retention either may be left un-
treated, as during permissive hypercapnia,15 or may be offset
totally or in part by extracorporeal support with lung mem-
brane16 or by washing the dead space with fresh gas delivery
into the trachea.17 Extracorporeal gas exchange devices focus
on carbon dioxide removal and oxygen exchange, avoid high
tidal volume and airway pressure, and provide temporary or
permanent respiratory life support even in the absence of
native pulmonary function.18 Extracorporeal membrane oxy-
genator technology is the most widely known and used clin-
ically19 and involves placing patients on a venovenous or
venoarterial life support circuit with a membrane oxygenator
to temporarily take over the gas exchange function of the
lung. During extracorporeal life support, the mechanical ven-
tilator settings can be reduced enough to reach nondamaging
settings, thereby minimizing ventilatory-induced lung injury
and maximizing both the recruitment of functional residual
lung capacity and the rest and healing of the residual injured
lungs. It has become the standard treatment of neonatal and
pediatric respiratory failure unresponsive to other modes of
treatment.20–22 Hemmila and associates23 have very recently
provided definitive evidence that extracorporeal life support
is a successful therapeutic option, even for adult patients
with severe (PaO2/FIO2 , 100) ARDS unresponsive to con-
ventional mechanical ventilator strategies. However, its use
has not gained wide acceptance, probably because of lack
of evidence and randomized trials, fear about the related com-
plications that are the rule and not the exception, team train-
ing, and costs.19
The extracorporeal lung membrane iLA used in this
experimental study has, however, several advantages over
other pump-driven devices. First, the iLA holds a very low-
resistance (7 mm Hg at blood flow of 0.5 to 2.5 L/min)
gas exchanger that requires only 20% to 30% of the CO as
a unique driving force when placed via a simple peripheral
percutaneous arteriovenous shunt to achieve extracorporeal
near-total carbon dioxide removal. Therefore, any roller
pump, a substantial portion of the tubing, and components
related to the extracorporeal membrane oxygenator are un-
necessary and potential related deleterious effects of foreign
surface areas, priming fluid, and blood transfusion volumes24
are avoided. Moreover, all the tubing and membrane have
a biologically active inner surface preventing local activation
of the clotting system; as a result, no systemic anticoagulationacic and Cardiovascular Surgery c Volume 135, Number 6 1369
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Second and third, since the iLA allows an extracorporeal
near-total carbon dioxide removal, the lungs are no longer re-
quired to supply a ventilatory function and can therefore be
minimally ventilated (eg, , 4 mg/mL). This is a condition
sine qua non not only to obtain a minimal but sufficient ‘‘na-
tive’’ oxygenation via apneic oxygenation but also to put the
damaged lungs at rest and give time to heal, according to the
rationales behind extracorporeal carbon dioxide removal and
apneic oxygenation elaborated by Kolobow,17 Gattinoni,16
and their associates.
All these theoretical hypotheses were recently used at the
bedside of patients with severe ppARDS and unresponsive to
standard conventional treatment, including conventional pro-
tective ventilation; the arteriovenous femoral placement was
well tolerated and was able to reduce the pulmonary morbid-
ity of the residual lung and improve the patient’s outcome.3
This present experimental study was started in parallel with
that clinical experience to compare, in attendance of a large
clinical trial whose difficulties to set up could be imagined,
standard protective ventilation with a maximal alveolar
ventilation in ppARDS obtained via iLA and near-static
ventilation. The severity of the surfactant-depletion ppARDS
did not differ among groups in terms of gas deterioration, he-
modynamic parameters, lung mechanics, or inflammatory re-
sponse of the injured lung. There were, however, significant
outcome differences among the groups in several respects.
All ppARDS animals treated with standard ventilatory set-
tings (tidal volume 10–12 mL/kg; minute volume 10 L/
min) died within 3 6 1 hours as a result of unresponsive
and progressive respiratory failure. This may be explained
by the double-edged sword effect of MV owing to the previ-
ously mentioned mechanisms. Animals with a ppARDS
receiving conventional treatment including standard protec-
tive ventilation had significantly more pulmonary morbidity
and poorer outcome (weaning and survival) than those
treated with iLA and near-static ventilation. Probably, this
may be explained by the fact that the iLA guaranteed not
only sufficient gas exchange, AVCO2R, and tissue oxygena-
tion but, most important, a near-static ventilation (minute
volume, 1.1 6 0.7 L/min), which minimized any further
ventilatory-induced injury of the injured residual lung. Under
this more protective status, the injured lungs were able to rest
and heal, as documented by the significantly lowered pulmo-
nary morbidity observed in iLA-treated pigs, for example,
attenuation of lung cytokines and restoration of surfactant
levels. This last restoration was probably the result of an ac-
tive process, for example, de novo production or secretion of
surfactant, because it is widely known that MV may inacti-
vate surfactant and increase alveolar surface tension.8
In conclusion, these animal model–based observations
reinforce our recent clinical findings regarding the advan-
tages of extracorporeal respiratory support in ppARDS.
They reveal that a protective ventilation strategy, including1370 The Journal of Thoracic and Cardiovascular Surgery c Jua pumpless extracorporeal lung membrane and alveolar hy-
poventilation, assures adequate gas exchange and affords
more protection of the injured residual lung than standard
protective ventilation. This in turn results in lower pulmonary
morbidity and better outcome. The detailed mechanisms un-
derlying these finding remain elusive and are likely multiple,
including less ventilatory-induced injury to the residual in-
jured lung, attenuation of the pulmonary inflammation, and
regeneration of surfactant.
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Discussion
Dr Bartley P. Griffith (Baltimore, Md). Dr Iglesias and Dr Mac-
chiarini, I thank you for what may be a paradigm-shifting manu-
script that may in fact change practice to a great degree in this
terrible postoperative complication.
[Slides] Some time ago I was interested in the laboratory with
pursuing arteriovenous extracorporeal membrane oxygenation as
an artificial placenta to mature newborn lamb lungs. We did not rec-
ognize then the importance of barotrauma, and we evaluated the
shunt required to normalize PO2. We early learned that by increasing
the shunt, we could change PO2, but the numbers required to do that
required a great strain on the heart.
The importance of this paper has been to confirm the concept that
Gattinoni brought to us of the ‘‘baby lung.’’ We must remember the
ARDS patient shown on this computed tomographic scan, the im-
portance of the defunctionalized lung that does not ventilate as op-
posed to the ventilated lung, which may be as little as a third of each
lung. Sixty-six percent of this patient’s lung would not be ventilated
and 33% would be ventilated, so even at a reserved low-volume
ventilation, that translates into about 18 mL/kg or high ventilation
volume to the normally ventilated lung, which we know from
ARDSNet to be counterproductive.
You have appropriately dissociated oxygenation andMV.Extrap-
ulmonary gas exchange replaces MV, which enables a therapeutic
window to protect the ventilation. The key to your study, of course,
is the low-resistance oxygenator that is now commercially available
in Europe and the fact that less than 20% of the CO needs to be
diverted into this oxygenator to achieve almost 300 mL of carbon
dioxide removal. While you ventilated with a PEEP of 19, your
end-inspiratory pressure was only 21. Your tidal volume was a third
of the ‘‘optimized’’ ventilated group and a fifth of the conventionally
ventilated group. Your minute volume was only 1 L, at a rate of 6.
Your model probably is not the same that we see clinically withThe Journal of ThorappARDS, but that is okay. I think what you have demonstrated is
lungprotection,which is thehallmark of treating this terrible problem.
I have two questions for you. Have you looked at various forms
of ventilation of your animals that might in fact even improve on the
outcomes that you had with the current experimental group? In other
words, have you tried continuous positive airway pressure as a ven-
tilatory method for these animals, extubating them very early?
Finally, have you measured cytokines in animals that did not
have anything other than the iLA associated with it? Early on in
my career, there was a lot of criticism about using artificial lung
membranes in patients with injured lungs for fear that cytokines
would in fact be elaborated.
Dr Iglesias. Thank you for your questions. To address the sec-
ond question, I performed a study accepted in the Journal of Tho-
racic and Cardiovascular Surgery where we placed the iLA in
axillary vascular access and then wemeasured the cytokine response
and did not find a systemic inflammatory response in this type of
pigs. It was done undergoing nothing for us. It practically inhaled
the pigs.
I did not understand your first question.
Dr Griffith. Could you forecast perhaps an even better form of
assisted ventilation to work in concert with the iLA, such as sponta-
neous continuous positive airway pressure?
Dr Iglesias. I refer this question to Dr Macchiarini.
DrMacchiarini. Thank you for the question. Yes, we did, in the
sense that as soon as you get on the iLA, you need to adapt the ven-
tilation and try the best setting in the sense that some respond very
well to pressure control and some to volume control. We found that
for the type of pneumonectomy that we did, a very simple pneumo-
nectomy, the pressure control ventilation was the simplest to man-
age. Whether or not this was because we had such a high level of
PEEP, I cannot tell you that, but it is a little bit parallel to what
we saw in the clinical experience on severe ppARDS. I would sug-
gest that from the experimental and clinical experience, so long as
you reach the target to reduce the tidal volumes as low as you
can, you might use either of the ventilation modes. We can go
even further. We tried to not ventilate the patients at all in the clinical
setting but simply keeping in place the tracheostomy tube or the tra-
cheal tube and putting a very low flow of oxygen, doing a sort of
apneic oxygenation. It did work as well. So there is a very large
variability among patients. Youmight try to use the best one adapted
to the patient, as long as you reach very low tidal volumes.
Dr Nasser K. Altorki (New York, NY). How long were the pigs
generally treated on the extracorporeal membrane oxygenator?
Were they also on some ancillary measures, such as steroids, or
were they just treated simply by the oxygenator?
Dr Iglesias. We treated with iLA in a total of 5 pigs among the
15 pigs in which we induced ARDS by surfactant depletion.
Dr Altorki. How many days were they on it after the ARDS
induction?
Dr Iglesias. Ninety minutes, more or less.cic and Cardiovascular Surgery c Volume 135, Number 6 1371
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CSPFigure E1. Correlation of oxygen (O2) transfer and arteriovenous
carbon dioxide (CO2) removal (AVCO2R) to the blood flow perfusing
the iLA device.1371.e1 The Journal of Thoracic and Cardiovascular Surgery c June 2008
Iglesias et al Cardiopulmonary Support and PhysiologyTABLE E1. Histologic grading of the severity and extension
of the lesions observed at postmortem examination in the
right lung
Severity score grading
Histopathologic findings Absent Mild Moderate Severe
Atelectasis 0 1 2 3
Bronchial epithelium
desquamative
0 1 2 3
Hyaline membranes 0 1 2 3
Exudative interstitial lesions 0 1 2 3
Exudative alveolar lesions 0 1 2 3
Extension score grading Focal Multifocal Diffuse
Extension of ARDS lesions 1 2 3CS
P
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CSPTABLE E2. Hemodynamic and lung permeability differences in ppARDS pigs observed only (group III), treated with
protective ventilation (group IV) or extracorporeal lung membrane (iLA) support (group V)
Variables Group III Group IV Group V P value
CO (L/min) 5.3 6 1 5.8 6 1 5.5 6 1* ,0.05
MAP (mm Hg) 80 6 22 77 6 6 64 6 4* 0.001
MPAP (mm Hg) 44.1 6 8 38.6 6 7.9 42.6 6 5.3 NS
SVR (Dyne/cm5) 1177 6 526 791 6 168 650 6 178* 0.001
PVR (Dyne/cm5) 451 6 117 325 6 113 301 6 109* 0.03
PCWP (mm Hg) 14 6 8 19 6 1 17 6 4* 0.001
CVP (mm Hg) 13 6 7 21 6 0.4 21 6 2* 0.01
Dpmax (mm Hg) 700 6 283.3 763.7 6 321.9 1029 6 422.5* 0.01
ELWI (mL/kg) 12 6 2 13 6 5 21 6 14* 0.01
ppARDS, Postpneumonectomy acute respiratory distress syndrome; CO, cardiac output;MAP, mean arterial pressure;MPAP, mean pulmonary arterial pres-
sure; SVR, systemic vascular resistance; RVP, pulmonary vascular resistance; PCWP, pulmonary capillary wedge pressure; CVP, central venous pressure;
Dpmax, ventricular contractibility, ELWI, index extra lung volume water; NS, not significant. *Comparison between groups V and III/IV.1371.e3 The Journal of Thoracic and Cardiovascular Surgery c June 2008
Iglesias et al Cardiopulmonary Support and PhysiologyTABLE E3. Kinetic of the lung cytokines over time in ppARDS treated with conventional treatment (group IV) and
extracorporeal lung membrane (iLA) support and near-static ventilation (group V)
Cytokines Group Baseline Pneumonectomy ppARDS 6-h ppARDS 12-h ppARDS
TNF-a IV 119 6 17 102 6 18 461 6 23 319 6 20 126 6 11
V 82 6 12 71 6 68 540 6 121 65 6 15 20 6 5*
IL-6 IV 9 6 2 30 6 15 386 6 125 384 6 35 50 6 17
V 2 6 1 10 6 4 384 6 55 243 6 20 6 6 3*
IL-8 IV 20 6 3 16 6 8 365 6 143 399 6 30 30 6 11
V 89 6 19 85 6 17 180 6 12 60 6 8 4 6 2*
ppARDS, Postpneumonectomy acute respiratory distress syndrome; TNF-a, tumor necrosis factor a; IL, interleukin. *Denotes statistical significance at
P , .05.CS
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